A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/DOXIL®/CAELYX®) In Combination Versus PLD In Participants With Platinum-Resistant Ovarian Cancer

• Conditions: Platinum Resistant Ovarian Cancer; MedDRA version: 14.0Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2011-000348-11-ES
• Lead Sponsor: Endocyte, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-07-28
• Last Update Posted: 27 October 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 640

Inclusion Criteria

1. Participants must sign an approved informed consent form (ICF).
2. Participants must be ? 18 years of age.
3. Participants must have pathology-confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
4. Participants must have at least a single (RECIST v1.1-defined) measurable lesion.
5. Participants must have received prior platinum-based chemotherapy for management of primary disease but must not have received more than 2 prior systemic cytotoxic regimens.
6. Participants must have platinum-resistant ovarian cancer. Note that primary or secondary platinum resistance is allowed. Participants with primary platinum-refractory disease are not allowed.
a. Primary platinum resistance is defined as disease that responded to primary platinum therapy and then progressed within 6 months of the last dose of primary platinum therapy.
b. Secondary platinum resistance is defined as disease that responded to primary platinum therapy and subsequently progressed during or within 6 months of completing secondary platinum therapy (ie, last platinum dose).
7. Participants are allowed to have received, but are not required to have received, one additional non-cytotoxic anti-tumor agent (eg, biologic or cytostatic) for the management of ovarian cancer.
8. For the purpose of obtaining a RECIST v1.1 baseline scan, participants must have a radiological evaluation conducted no more than 28 days prior to beginning study therapy (EC145/Placebo and PLD).
a. For participants with a history of CNS metastasis, baseline radiological imaging must include evaluation of the head.
9. Participants must have had prior debulking surgery (with the exception of participants who have primary peritoneal carcinoma not requiring debulking surgery).
10. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
11. Participants must have recovered (to baseline/stabilization) from prior cytotoxic therapy-associated acute toxicities. Participants who have recovered from non-cytotoxic therapy-associated toxicity or who have ?controlled? non-cytotoxic therapy toxicity (eg, vascular endothelial growth factor [VEGF]-related hypertension) can be entered into the trial after a drug wash-out period of 4 half lives.
12. Participants must have adequate organ function including:
i. Bone marrow reserve:
a) Absolute neutrophil count (ANC) ? 1.5 x 10^9/L prior to treatment (1.5 x 10^9/L is equivalent to 1.5 x 10^3/µL and 1.5 x K/µL and 1.5 x 10^3/cumm and 1500/µL). Participants on maintenance doses of granulocyte colony stimulating factor (G CSF) are eligible.
b) Platelets ? 100 x 10^9/L (100 x 10^9/L is equivalent to 100 x 10^3/µL and 100 x K/µL and 100 x 10^3/cumm and 100000/µL)
c) Hemoglobin ? 9 g/dL (9 g/dL is equivalent to 90 g/L and 5.59 mmol/L).
d) Use of supportive care measures (eg, use of white blood cell [WBC] growth factors, antiemetics, epoetin) should follow the ASCO guidelines as listed at www.asco.org. Participants should receive full supportive care, including transfusion of blood as mandated by clinical need; however, transfusions administered for the sole purpose of meeting the study inclusion criteria between the time informed consent is signed and first dose of EC145/placebo/PLD is administered are not allowed.
ii. Hepatic: Total bilirubin level ? 1.5 x ULN and alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), and alkaline phosphatase levels ? 2.5 x ULN.
i

Exclusion Criteria

1. Participants? refractory to primary platinum therapy where ?refractory? is defined as disease progression within 6 months of first dose of initial platinum-based therapy.
2. Diagnosis of ?tumor of low-malignant potential.?
3. Prior exposure to PLD or anthracycline therapy.
4. Prior exposure to FR-targeted therapy (eg, EC145, EC0225, EC0489, farletuzumab).
5. Prior therapy with vinorelbine (Navelbine®) or vinca-containing compounds.
6. Prior abdominal or pelvic radiation therapy or radiation therapy to > 10% of the bone marrow at any time in the past; or prior radiation therapy within the past 3 years to the breast/sternum, dermal lesions, head, or neck.
7. Recent (ie, ? 6 weeks) history of abdominal surgery or peritonitis.
8. Serious comorbidities (as determined by the investigator) such as, but not limited to, active congestive heart failure or recent myocardial infarction. Participants who require antifolate therapy for the management of comorbid conditions (eg, rheumatoid arthritis) will be excluded from the trial.
9. Pregnant or nursing.
10. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).
11. Symptomatic central nervous system (CNS) metastasis.
12. Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (ie, used for non-approved indications(s) and in the context of a research investigation). Use of low dose corticosteroid therapy (eg, for nausea prophylaxis) is acceptable; however, concomitant tamoxifen therapy is not. Supportive care measures are allowed.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified